A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis

NCT00257855 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Secondary Progressive Multiple Sclerosis

Interventions

DRUG: Lamotrigine

Sponsor

University College London Hospitals